Efficacy and safety of oral ibrexafungerp in Chinese patients with vulvovaginal candidiasis: a phase III, randomized, double-blind study

安慰剂 医学 内科学 氟康唑 临床终点 不利影响 外阴阴道念珠菌病 白色念珠菌 临床试验 随机对照试验 胃肠病学 皮肤病科 抗真菌 替代医学 病理 生物 遗传学
作者
Xiaoqian Wang,Wenying Wang,Jing Wang,Ruifang An,Lihong Chen,Jiajing Lin,Dabao Xu,Jin Qiu,Weihua Song,Mijiti Patiman,Hongjie Ruan,Gang Wang,Fengxia Xue,Sheng Wang,Xiaowan Luo,Qiuqi Ruan,Ling Shi,Chun Zhang,Lina Hu,Shijin Wang,S-H Hong,Zhenjun Li,Songling Zhang,Yingxiong Li,Jing Lu,Bao-jin Wang,Hongyan Xu,Ye Hong,Bei Zhang,Chunlian Zhang,Sumin Qian,Qiong Wu,Jia Wen,Chuan Li,Qinping Liao
出处
期刊:Infection [Springer Science+Business Media]
标识
DOI:10.1007/s15010-024-02233-w
摘要

Abstract Purpose To evaluate the efficacy and safety of oral ibrexafungerp (HS-10366) versus placebo in Chinese patients with vulvovaginal candidiasis (VVC). Methods A double-blind, placebo-controlled, randomized, multicenter phase III study was conducted in symptomatic VVC patients. Patients received (2:1) twice-daily oral ibrexafungerp 300 mg or matching placebo for 1 day. The primary endpoint was clinical cure (vulvovaginal signs and symptoms [VSS] score = 0) at test-of-cure (TOC) on day 11 ± 3. The secondary endpoints included mycological eradication, overall response, and clinical improvement (VSS score ≤ 1) at TOC, and vulvovaginal symptom resolution at follow-up on day 25 ± 4. Results In total, 360 patients were included in the modified intention-to-treat set (defined as positive Candida cultured and receiving at least one study drug; 239 for ibrexafungerp, 121 for placebo). Compared with placebo, patients receiving ibrexafungerp had a significantly higher proportion of clinical cure (51.0% vs. 25.6%), mycological eradication (55.6% vs. 18.2%), overall response (33.9%, vs. 8.3%) at TOC and complete symptom resolution (74.5% vs. 39.7%, all P < 0.001) at follow-up. Subgroup analysis of clinical cure indicated that patients with C. albicans could benefit from ibrexafungerp over placebo. A similar benefit trend was also observed in those with non- albicans Candida by post-hoc analysis. Further analyses revealed similar efficacy of ibrexafungerp between patients with fluconazole non-susceptible C. albicans and fluconazole susceptible C. albicans regarding clinical cure and mycological eradication. Ibrexafungerp was generally well tolerated. Adverse events were primarily gastrointestinal and were mainly mild in severity. Conclusions As a first-in-class antifungal agent, ibrexafungerp demonstrated promising efficacy and favorable safety for VVC treatment in Chinese patients. Chinadrugtrials.org.cn registry number CTR20220918.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
jiaolulu发布了新的文献求助10
刚刚
小王发布了新的文献求助10
1秒前
queen814完成签到,获得积分10
1秒前
简单发布了新的文献求助10
2秒前
一只呆果蝇完成签到,获得积分10
2秒前
Eternity完成签到,获得积分10
3秒前
研友_VZG7GZ应助落后从阳采纳,获得10
3秒前
乐观寻绿完成签到,获得积分10
4秒前
Hover完成签到,获得积分0
4秒前
莫晓岚完成签到,获得积分10
4秒前
123完成签到 ,获得积分10
5秒前
所所应助JSY采纳,获得30
5秒前
默默的立辉完成签到,获得积分10
5秒前
Yh完成签到,获得积分10
5秒前
引子完成签到,获得积分10
7秒前
机智的阿振完成签到,获得积分10
8秒前
KatzeBaliey完成签到,获得积分10
9秒前
量子星尘发布了新的文献求助10
10秒前
yar应助大饼采纳,获得10
11秒前
mammer应助一朵云采纳,获得20
11秒前
11秒前
Jason完成签到,获得积分10
12秒前
害羞凤灵完成签到,获得积分10
12秒前
芳芳完成签到,获得积分10
13秒前
风起枫落完成签到 ,获得积分10
13秒前
xkhxh完成签到 ,获得积分10
14秒前
zzq778发布了新的文献求助10
14秒前
小马甲应助双儿采纳,获得10
15秒前
江南烟雨如笙完成签到 ,获得积分10
16秒前
王洋应助枕星采纳,获得10
19秒前
笨笨寒天完成签到,获得积分10
19秒前
Hello应助zzq778采纳,获得10
19秒前
20秒前
铜豌豆完成签到 ,获得积分10
20秒前
稞小弟完成签到,获得积分10
20秒前
21秒前
23秒前
23秒前
zzzz发布了新的文献求助10
24秒前
小马完成签到,获得积分10
26秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029